biOasis' BT2111-Herceptin(R) Program Achieves Significant Positive Results From Antibody Dependent Cell-Mediated Cytotoxicity Assay
3/13/2012 7:25:38 AM
More...
|
biOasis Announces Transcend Vector Results With a Therapeutic Antibody That Targets Metastatic Breast Cancer
7/6/2011 10:16:51 AM
More...
|
biOasis Director Resigns
6/24/2011 10:49:10 AM
More...
|
biOasis to Present on Drug Delivery at International Conference on Cerebral Vascular Biology
6/22/2011 9:18:51 AM
More...
|
biOasis Initiates Transcend Vector Program Targeting Treatments for CNS Symptoms of Lysosomal Storage Disorders
5/11/2011 9:47:35 AM
More...
|
biOasis Receives Verification That Transcend Localizes to a Number of Cell Types in the Brain
5/2/2011 9:22:49 AM
More...
|
biOasis Adds MarketSmart Communications Inc. to Investor Relations Team
4/18/2011 12:22:40 PM
More...
|
biOasis Director Resigns
4/14/2011 1:28:47 PM
More...
|
biOasis Receives Significant Independent Results From Its Transcend Program
4/14/2011 1:10:37 PM
More...
|
biOasis Poster Being Presented at 17th Annual Blood-Brain Barrier Consortium Meeting
3/24/2011 10:31:00 AM
More...
|
|